JP7179014B2 - ニラパリブの製造方法 - Google Patents

ニラパリブの製造方法 Download PDF

Info

Publication number
JP7179014B2
JP7179014B2 JP2019557567A JP2019557567A JP7179014B2 JP 7179014 B2 JP7179014 B2 JP 7179014B2 JP 2019557567 A JP2019557567 A JP 2019557567A JP 2019557567 A JP2019557567 A JP 2019557567A JP 7179014 B2 JP7179014 B2 JP 7179014B2
Authority
JP
Japan
Prior art keywords
formula
salt
acid
compound
monohydrate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019557567A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020517668A (ja
JP2020517668A5 (enExample
Inventor
アリステア、スチュワート
アンソニー、ジョセフ、トト
フランク、シン、チェン
ジョージ、ウー
Original Assignee
テサロ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by テサロ， インコーポレイテッド filed Critical テサロ， インコーポレイテッド
Publication of JP2020517668A publication Critical patent/JP2020517668A/ja
Publication of JP2020517668A5 publication Critical patent/JP2020517668A5/ja
Application granted granted Critical
Publication of JP7179014B2 publication Critical patent/JP7179014B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C303/00—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides
    • C07C303/32—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of salts of sulfonic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C303/00—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides
    • C07C303/42—Separation; Purification; Stabilisation; Use of additives
    • C07C303/44—Separation; Purification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/70—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D211/74—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
JP2019557567A 2017-04-24 2018-04-24 ニラパリブの製造方法 Active JP7179014B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762489415P 2017-04-24 2017-04-24
US201762489387P 2017-04-24 2017-04-24
US62/489,387 2017-04-24
US62/489,415 2017-04-24
PCT/US2018/029131 WO2018200517A1 (en) 2017-04-24 2018-04-24 Methods of manufacturing of niraparib

Publications (3)

Publication Number Publication Date
JP2020517668A JP2020517668A (ja) 2020-06-18
JP2020517668A5 JP2020517668A5 (enExample) 2021-06-17
JP7179014B2 true JP7179014B2 (ja) 2022-11-28

Family

ID=63919973

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019557567A Active JP7179014B2 (ja) 2017-04-24 2018-04-24 ニラパリブの製造方法

Country Status (15)

Country Link
US (2) US11161834B2 (enExample)
EP (1) EP3615513B1 (enExample)
JP (1) JP7179014B2 (enExample)
KR (1) KR102582624B1 (enExample)
CN (2) CN110753684A (enExample)
AU (2) AU2018258274C1 (enExample)
CA (1) CA3060715C (enExample)
ES (1) ES2926255T3 (enExample)
IL (1) IL270068B (enExample)
MA (1) MA48475A (enExample)
MX (1) MX393879B (enExample)
SG (1) SG11201909807TA (enExample)
TW (1) TWI783993B (enExample)
WO (1) WO2018200517A1 (enExample)
ZA (1) ZA201906944B (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201811564QA (en) 2016-06-29 2019-01-30 Tesaro Inc Methods of treating ovarian cancer
MX2019011496A (es) 2017-03-27 2020-01-23 Tesaro Inc Composiciones de niraparib.
JP7179014B2 (ja) 2017-04-24 2022-11-28 テサロ， インコーポレイテッド ニラパリブの製造方法
KR20200018436A (ko) 2017-05-09 2020-02-19 테사로, 인코포레이티드 암 치료를 위한 조합 요법
CA3063715A1 (en) 2017-05-18 2018-11-22 Tesaro, Inc. Combination therapies for treating cancer
EA202090573A1 (ru) 2017-09-26 2020-09-07 Тесаро, Инк. Составы нирапариба
JP2020536066A (ja) 2017-09-30 2020-12-10 テサロ， インコーポレイテッド 癌を治療するための併用療法
CN111182923A (zh) 2017-10-06 2020-05-19 特沙诺有限公司 组合疗法及其用途
EP3860988A1 (en) 2018-10-03 2021-08-11 Tesaro, Inc. Crystalline forms of niraparib freebase
CN112300074B (zh) * 2019-08-02 2023-12-29 北京盈科瑞创新药物研究有限公司 一种吲唑甲酰胺类化合物及其制备方法和应用
WO2023159066A1 (en) 2022-02-15 2023-08-24 Tesaro, Inc. Use of niraparib for the treatment of brain cancer
WO2024142096A1 (en) * 2022-12-29 2024-07-04 Dr. Reddy’S Laboratories Limited Process for preparation of niraparib tosylate and its intermediates
WO2025017711A1 (en) * 2023-07-20 2025-01-23 Natco Pharma Limited An improved process for the preparation of niraparib tosylate monohydrate

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010515715A (ja) 2007-01-10 2010-05-13 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー ポリ（ａｄｐ−リボース）ポリメラーゼ（ｐａｒｐ）阻害剤としてのアミド置換インダゾール
JP2011509252A (ja) 2008-01-08 2011-03-24 メルク シャープ エンド ドーム リミテッド ２−｛４−［（３ｓ）−ピペリジン−３−イル］フェニル｝−２ｈ−インダゾール−７−カルボキサミドの薬学的に許容される塩
WO2014088983A1 (en) 2012-12-07 2014-06-12 Merck Sharp & Dohme Corp. Regioselective n-2 arylation of indazoles

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5837458A (en) 1994-02-17 1998-11-17 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
US6335160B1 (en) 1995-02-17 2002-01-01 Maxygen, Inc. Methods and compositions for polypeptide engineering
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
FI104465B (fi) 1995-06-14 2000-02-15 Valio Oy Proteiinihydrolysaatteja allergioiden hoitamiseksi tai estämiseksi, niiden valmistus ja käyttö
JP4213771B2 (ja) 1997-04-23 2009-01-21 株式会社カネカ 光学活性アミノ化合物の製造方法
WO1999029902A1 (en) 1997-12-08 1999-06-17 California Institute Of Technology Method for creating polynucleotide and polypeptide sequences
JP4221100B2 (ja) 1999-01-13 2009-02-12 エルピーダメモリ株式会社 半導体装置
GB0004297D0 (en) 2000-02-23 2000-04-12 Ucb Sa 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses
EP1272967A2 (en) 2000-03-30 2003-01-08 Maxygen, Inc. In silico cross-over site selection
CN1854128B (zh) 2001-04-24 2012-05-16 麻省理工学院 铜-催化的碳-杂原子键和碳-碳键的形成
JPWO2002100833A1 (ja) 2001-06-12 2004-09-24 住友製薬株式会社 Ｒｈｏキナーゼ阻害剤
CN101048397A (zh) 2004-09-29 2007-10-03 三菱制药株式会社 作为τ蛋白激酶1抑制剂的6－（吡啶基）－4－嘧啶酮衍生物
JP4611441B2 (ja) 2006-04-03 2011-01-12 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー ポリ（ａｄｐ−リボース）ポリメラーゼ（ｐａｒｐ）阻害剤としてのアミド置換インダゾール及びベンゾトリアゾール誘導体
US7998961B2 (en) 2006-08-31 2011-08-16 Schering Corporation Hydantoin derivatives useful as antibacterial agents
EP2132322A4 (en) 2007-03-02 2013-02-20 Richmond Chemical Corp METHOD FOR INCREASING YIELD AND IMPROVING PURIFICATION OF PRODUCTS FROM REACTIONS WITH TRANSAMINASE
AR065804A1 (es) * 2007-03-23 2009-07-01 Smithkline Beecham Corp Compuesto de indol carboxamida, composicion farmaceutica que lo comprende y uso de dicho compuesto para preparar un medicamento
WO2008132142A2 (en) 2007-04-27 2008-11-06 Ucb Pharma S.A. New heterocyclic derivatives useful for the treatment of cns disorders
SG173815A1 (en) 2009-02-26 2011-09-29 Codexis Inc Transaminase biocatalysts
JP2010269667A (ja) 2009-05-20 2010-12-02 Alps Electric Co Ltd 多回転角度検出装置
EP2606139B1 (en) 2010-08-16 2015-07-15 Codexis, Inc. Biocatalysts and methods for the synthesis of (1r,2r)-2-(3,4-dimethoxyphenethoxy)cyclohexanamine
KR20140001965A (ko) 2010-11-30 2014-01-07 다케다 야쿠힌 고교 가부시키가이샤 바이시클릭 화합물
KR101585840B1 (ko) 2011-02-08 2016-01-15 화이자 인코포레이티드 글루카곤 수용체 조절자
US8802673B2 (en) 2011-03-24 2014-08-12 Hoffmann-La Roche Inc Heterocyclic amine derivatives
US9073911B2 (en) 2011-06-09 2015-07-07 Hoffmann-La Roche Inc. Pyrazole derivatives
PT2928865T (pt) 2012-12-07 2018-06-11 Merck Sharp & Dohme Processo de transaminação biocatalítica
US20160160294A1 (en) 2014-12-08 2016-06-09 Tesaro Methods and materials for predicting response to niraparib
SG11201811564QA (en) 2016-06-29 2019-01-30 Tesaro Inc Methods of treating ovarian cancer
CN106496187A (zh) * 2016-09-14 2017-03-15 陕西科技大学 一种制备PARP抑制剂Niraparib的合成方法
CN106432056A (zh) * 2016-09-17 2017-02-22 青岛辰达生物科技有限公司 一种尼拉帕布中间体(3s)‑3‑(4‑氨基苯基)哌啶‑1‑甲酸叔丁酯的制备方法
CN106432055A (zh) 2016-09-17 2017-02-22 青岛辰达生物科技有限公司 一种尼拉帕布中间体4‑（哌啶‑3‑基）苯胺的制备方法
CN106432057A (zh) * 2016-09-17 2017-02-22 青岛云天生物技术有限公司 一种制备(3s)‑3‑(4‑氨基苯基)哌啶‑1‑甲酸叔丁酯的方法
MX2019011496A (es) 2017-03-27 2020-01-23 Tesaro Inc Composiciones de niraparib.
BR112019020191A2 (pt) 2017-03-27 2020-04-22 Tesaro Inc formulações de niraparib
JP7179014B2 (ja) 2017-04-24 2022-11-28 テサロ， インコーポレイテッド ニラパリブの製造方法
KR20200018436A (ko) 2017-05-09 2020-02-19 테사로, 인코포레이티드 암 치료를 위한 조합 요법
CA3063715A1 (en) 2017-05-18 2018-11-22 Tesaro, Inc. Combination therapies for treating cancer
EA202090573A1 (ru) 2017-09-26 2020-09-07 Тесаро, Инк. Составы нирапариба
JP2020536066A (ja) 2017-09-30 2020-12-10 テサロ， インコーポレイテッド 癌を治療するための併用療法
CN111182923A (zh) 2017-10-06 2020-05-19 特沙诺有限公司 组合疗法及其用途
JP7337805B2 (ja) 2017-12-27 2023-09-04 テサロ， インコーポレイテッド がんを処置する方法
MX2020008258A (es) 2018-02-05 2020-11-13 Tesaro Inc Formulaciones pediátricas de niraparib y métodos de tratamiento pediátricos.

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010515715A (ja) 2007-01-10 2010-05-13 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー ポリ（ａｄｐ−リボース）ポリメラーゼ（ｐａｒｐ）阻害剤としてのアミド置換インダゾール
JP2011509252A (ja) 2008-01-08 2011-03-24 メルク シャープ エンド ドーム リミテッド ２−｛４−［（３ｓ）−ピペリジン−３−イル］フェニル｝−２ｈ−インダゾール−７−カルボキサミドの薬学的に許容される塩
WO2014088983A1 (en) 2012-12-07 2014-06-12 Merck Sharp & Dohme Corp. Regioselective n-2 arylation of indazoles

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Chung, Cheol K.，Process Development of C-N Cross-Coupling and Enantioselective Biocatalytic Reactions for the Asymmetric Synthesis of Niraparib，Organic Process Research & Development ，2014年，18(1),，215-227
Wallace, Debra J.，Development of a Fit-for-Purpose Large-Scale Synthesis of an Oral PARP Inhibitor，Organic Process Research & Development，2011年，15(4),，831-840

Also Published As

Publication number Publication date
JP2020517668A (ja) 2020-06-18
AU2021215116B2 (en) 2022-12-01
MA48475A (fr) 2020-03-04
US20220041575A1 (en) 2022-02-10
IL270068B (en) 2022-06-01
ES2926255T3 (es) 2022-10-24
CN118271233A (zh) 2024-07-02
NZ758948A (en) 2024-04-26
AU2018258274C1 (en) 2021-12-02
SG11201909807TA (en) 2019-11-28
CN110753684A (zh) 2020-02-04
TWI783993B (zh) 2022-11-21
ZA201906944B (en) 2023-03-29
AU2021215116A1 (en) 2021-08-26
WO2018200517A1 (en) 2018-11-01
CA3060715C (en) 2024-10-01
EP3615513B1 (en) 2022-07-20
AU2018258274B2 (en) 2021-05-13
US20200055837A1 (en) 2020-02-20
US11161834B2 (en) 2021-11-02
KR102582624B1 (ko) 2023-09-22
TW201841889A (zh) 2018-12-01
EP3615513A1 (en) 2020-03-04
US11629137B2 (en) 2023-04-18
EP3615513A4 (en) 2020-12-09
MX393879B (es) 2025-03-24
AU2018258274A1 (en) 2019-11-14
BR112019022320A2 (pt) 2020-05-26
CA3060715A1 (en) 2018-11-01
KR20200021456A (ko) 2020-02-28

Similar Documents

Publication Publication Date Title
JP7179014B2 (ja) ニラパリブの製造方法
HU219911B (hu) Pirazolo-piridin-származékok, alkalmazásuk és ezeket tartalmazó gyógyászati készítmények
EP3310772A1 (en) Spiro[cyclobutane-1,3'-indolin]-2'-one derivatives as bromodomain inhibitors
WO2017197192A1 (en) Spirocycle compounds and methods of making and using same
WO2024148191A1 (en) MODULATORS OF TNF-α ACTIVITY
US12435086B2 (en) Synthesis of heterocyclic compounds
WO2009016653A1 (en) Stable polymorphic form of paliperidone and process for its preparation
CN102471326B (zh) 硫杂苯并薁丙酸衍生物的制备方法
CN117500787A (zh) 二甲基色胺的新型前药和缀合物
HK40025665A (en) Methods of manufacturing of niraparib
HK40025665B (en) Methods of manufacturing of niraparib
EA044378B1 (ru) Способы изготовления нирапариба
BR112019022320B1 (pt) Processo para preparar niraparibe
KR20170080190A (ko) 1,5-쌍극자의 [5+3] 고리화 첨가 반응을 이용한 8원 헤테로 고리 화합물의 제조 방법 및 이에 의해 제조된 8원 헤테로 고리 화합물
WO2022271557A1 (en) Processes for the preparation of (s)-2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl) methyl)benzyl) amino)isoindoline-1,3-dione
KR101346555B1 (ko) 9-히드록시-3-(2-클로로에틸)-2-메틸-6,7,8,9-테트라히드로-4Ｈ-피리도[1,2-ａ]피리미딘-4-온의 제조방법

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210426

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210426

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220310

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220315

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220615

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20221018

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20221115

R150 Certificate of patent or registration of utility model

Ref document number: 7179014

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250